(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

MÉTODOS DE REDUZIR EFEITOS COLATERAIS DE TERAPIA DE CONJUGADO ANTICORPO ANTI-CD30 FÁRMACO

Em ExigênciaInvention PatentPCT · US2018055354

Application data

Number

112020006892

Type

Invention Patent

Filing

10/11/2018

Publication

10/06/2020

PCT

US2018055354

Progress at the INPI

Technical opinion to answer
  1. Filing10/11/18
  2. Publication10/06/20
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 08/16/2022. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

SEAGEN INC.

US

SEATTLE GENETICS, INC.

US

See this company's full portfolio

Inventors

N. J. (pessoa física)

US

T. M. (pessoa física)

US

Technical data

IPC Classification

Priority claims

US

62/570,901 · 10/11/2017

US

62/580,267 · 11/01/2017

US

62/639,308 · 03/06/2018

US

62/764,805 · 08/16/2018

Abstract

A presente invenção refere-se, em geral, a métodos para melhorar eventos adversos em sujeitos recebendo tratamento com um conjugado de anticorpo anti-CD30 fármaco, opcionalmente também recebendo quimioterapia associada. Os eventos adversos incluem neuropatia periférica e neutropenia.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Parecer de pré-exame

#6.23

08/16/2022

RPI 2693

Alteração de nome deferida

#25.4

03/22/2022

RPI 2672

Adição na publicação

#15.35

11/23/2021

RPI 2655

Notificação de entrada na fase nacional - PCT

#1.3

10/06/2020

RPI 2596

Alteração de dados cadastrais

#1.1

09/15/2020

RPI 2593

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.